XML 55 R26.htm IDEA: XBRL DOCUMENT
v3.3.0.814

Collaboration Agreements - Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue (Detail) $ in Thousands | Sep. 30, 2015 USD ($)
--- | ---
Astellas Agreement [Member] | Japan [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | $ 44,119
Deferred Revenue | 65
Total Consideration | 44,184
Astellas Agreement [Member] | Japan [Member] | License [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 42,163
Deferred Revenue | 0
Total Consideration | 42,163
Astellas Agreement [Member] | Japan [Member] | When and if available compounds [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 14
Deferred Revenue | 28
Total Consideration | 42
Astellas Agreement [Member] | Japan [Member] | Manufacturing-clinical supplies [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 1,926
Deferred Revenue | 36
Total Consideration | 1,962
Astellas Agreement [Member] | Japan [Member] | Committee services [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 16
Deferred Revenue | 1
Total Consideration | 17
Astellas Agreement [Member] | Europe [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 439,113
Deferred Revenue | 643
Total Consideration | 439,756
Astellas Agreement [Member] | Europe [Member] | License [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 397,369
Deferred Revenue | 0
Total Consideration | 397,369
Astellas Agreement [Member] | Europe [Member] | When and if available compounds [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 320
Deferred Revenue | 436
Total Consideration | 756
Astellas Agreement [Member] | Europe [Member] | Manufacturing-clinical supplies [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 9,318
Deferred Revenue | 200
Total Consideration | 9,518
Astellas Agreement [Member] | Europe [Member] | Committee services [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 268
Deferred Revenue | 7
Total Consideration | 275
Astellas Agreement [Member] | Europe [Member] | Development services-in progress [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 31,838
Deferred Revenue | 0
Total Consideration | 31,838
AstraZeneca Agreements [Member] | U.S./RoW [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 320,489
Deferred Revenue | 97,993
Total Consideration | 418,482
AstraZeneca Agreements [Member] | U.S./RoW [Member] | License [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 277,132
Deferred Revenue | 0
Total Consideration | 277,132
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Manufacturing-clinical supplies [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 197
Deferred Revenue | 91
Total Consideration | 288
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Co-development, information sharing & committee services [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 43,160
Deferred Revenue | 41,097
Total Consideration | 84,257
AstraZeneca Agreements [Member] | U.S./RoW [Member] | China-single unit of accounting [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 0
Deferred Revenue | 56,805
Total Consideration | $ 56,805

X
- Definition The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition. + References No definition available. + Details
Name: | fgen_CashConsiderationReceivedUnderCollaborationAgreement
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Total amount of revenue recognized for license and collaboration services under the collaboration agreement as of a given date. + References No definition available. + Details
Name: | fgen_CumulativeRevenueLicenseAndCollaborationServicesRevenueRecognized
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_JP
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=fgen_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=fgen_WhenAndIfAvailableCompoundsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=fgen_ManufacturingClinicalSuppliesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=fgen_CommitteeServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=fgen_DevelopmentServicesInProgressMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=fgen_ChinaSingleUnitOfAccountingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |